Treatment of Short Bowel Syndrome Patients with Colon-in-Continuity

Abstract

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

We claim: 
     
         1 . A method of treating an adult human patient having short bowel syndrome with equal or elevated meal stimulated levels of endogenous GLP-2 (as compared to a normal healthy individual), who receives an amount of parenteral nutrition each week, and who presents with colon-in-continuity with remnant small intestine, said method comprising administering [Gly2]hGLP-2 to said patient using a dosing regimen effective to reduce or eliminate said weekly amount of parenteral nutrition received by said patient. 
     
     
         2 . The method as defined in  claim 1 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 5 to 500 μg/kg. 
     
     
         3 . The method as defined in  claim 2 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg. 
     
     
         4 . The method as defined in  claim 1 , wherein the [Gly2]hGLP-2 is administered by subcutaneous injection. 
     
     
         5 . The method as defined in  claim 4 , wherein the subcutaneous injection is into the abdomen, thigh, or arm. 
     
     
         6 . A method of treating an adult human patient having short bowel syndrome with equal or elevated meal stimulated levels of endogenous GLP-2 (as compared to a normal healthy individual), who receives an amount of parenteral nutrition each week, and who presents with colon-in-continuity with remnant small intestine, said method comprising administering [Gly2]hGLP-2 to said patient using a dosing regimen effective to increase wet weight absorption compared to a baseline wet weight absorption by said patient. 
     
     
         7 . The method as defined in  claim 6 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 5 to 500 μg/kg. 
     
     
         8 . The method as defined in  claim 7 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg. 
     
     
         9 . The method as defined in  claim 6 , wherein the [Gly2]hGLP-2 is administered by subcutaneous injection. 
     
     
         10 . The method as defined in  claim 9 , wherein the subcutaneous injection is into the abdomen, thigh, or arm. 
     
     
         11 . The method as defined in  claim 1 , wherein said regimen comprises administration of said [Gly2]hGLP-2 over a period of at least 21 days. 
     
     
         12 . The method as defined in  claim 6 , wherein said regimen comprises administration of said [Gly2]hGLP-2 over a period of at least 21 days. 
     
     
         13 . The method as defined in  claim 1 , wherein the parenteral nutrition is reduced by volume or frequency of administration. 
     
     
         14 . The method as defined in  claim 1 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg by subcutaneous injection. 
     
     
         15 . The method as defined in  claim 6 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg by subcutaneous injection.